Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many other ...

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, ...

University of California San Diego researchers have identified a U-shaped association between high-density lipoprotein (HDL) ...

The following is a summary of “Neuroretinal and RPE changes and susceptibility to Age-Related Macular Degeneration: insights ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...

High and low levels of high-density lipoprotein and a novel single-nucleotide polymorphism were found to be associated with ...